Vanesa B. M.
- Country
- Spain
- Department
- Gastroenterology Hepatology
Research Overview
- HepaStem Long-Term Safety Registry – Registry for Patients who have been administered HepaStem
- Phase III Randomized Double‑Blind Placebo‑Controlled Study of Oral Elafibranor 120 mg in Adults with Primary Sclerosing Cholangitis
- Efficacy and Safety Evaluation of Pemafibrate and Tofogliflozin Combination in Noncirrhotic NASH with Liver Fibrosis: A Phase 2 Randomized, Double-Blind Study
Data & Insights
Has run more than one trial at 55 of 174 partner sites.
Specializations
Liver Disease Management
This investigator specializes in the treatment of chronic liver disease, with particular emphasis on managing advanced stages and improving patient outcomes.
- Advanced Chronic Liver Disease (cACLD)
- Liver Disease Progression
- Clinical Event Prevention
The research focus includes innovative therapeutic approaches for managing chronic liver conditions and their complications.
Cholestatic Liver Disorders
Expertise in treating Primary Biliary Cholangitis (PBC), a chronic autoimmune liver disease, with particular attention to patients who show inadequate response to conventional treatments.
- Autoimmune Liver Disease
- Treatment-Resistant PBC
- Liver Function Markers
The investigator explores novel therapeutic options for patients with challenging presentations of biliary disorders.
Advanced Hepatic Care
Focused on the management of liver cirrhosis and its complications, particularly in the context of primary biliary cholangitis.
- Cirrhosis Management
- Long-term Disease Outcomes
- Clinical Event Prevention
The research encompasses long-term therapeutic strategies for advanced liver conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.